Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine

NCT00559975 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza Infection

Interventions

BIOLOGICAL: Subunit influenza vaccine
BIOLOGICAL: Adjuvanted influenza vaccine
BIOLOGICAL: Adjuvanted influenza vaccine combined with CpG7909
BIOLOGICAL: Adjuvanted influenza vaccine combine with CpG7909
BIOLOGICAL: Adjuvanted influenza vaccine combine with CpG7909

Sponsor

Novartis

Collaborators

[object Object]